Literature DB >> 29264761

Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer.

Enora Laas1,2, Marcos Ballester3,4,5, Annie Cortez4,6, Olivier Graesslin7, Emile Daraï3,4,5.   

Abstract

Considerable heterogeneity exists in outcomes of early endometrial cancer (EC) according to the type but also the histological grading. Our goal was to describe the immunohistochemical profiles of type I EC according to grades and type II EC, to identify groups of interacting proteins using principal component analysis (PCA) and unsupervised clustering. We studied 13 immunohistochemical markers (steroid receptors, pro/anti-apoptotic proteins, metalloproteinases (MMP) and tissue inhibitor of metalloproteinase (TIMP), and CD44 isoforms known for their role in endometrial pathology. Co-expressed proteins associated with the type, grade and outcome of EC were determined by PCA and unsupervised clustering. PCA identified three functional groups of proteins from 43 tissue samples (38 type I and 5 type II EC): the first was characterized by p53 expression; the second by MMPs, bcl-2, PR B and CD44v6; and the third by ER alpha, PR A, TIMP-2 and CD44v3. Unsupervised clustering found two main clusters of proteins, with both type I grade 3 and type II EC exhibiting the same cluster profile. PCA and unsupervised clustering of immunohistochemical markers in EC contribute to a better comprehension and classification of the disease.

Entities:  

Keywords:  Endometrial cancer; High-risk endometrial cancer; Immunohistochemistry; Principal component analysis; Unsupervised clustering

Mesh:

Substances:

Year:  2017        PMID: 29264761     DOI: 10.1007/s12253-017-0335-y

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  1 in total

1.  In-depth comparative analysis of Illumina® MiSeq run metrics: Development of a wet-lab quality assessment tool.

Authors:  George John Kastanis; Luis V Santana-Quintero; Maria Sanchez-Leon; Sara Lomonaco; Eric W Brown; Marc W Allard
Journal:  Mol Ecol Resour       Date:  2019-01-17       Impact factor: 7.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.